NIH Awards UM1 Funding to Establish PReDicTR Consortium
Rada Savic, PhD and colleagues Eric Nuermberger, MD (JHU), Kelly Dooley, MD, PhD, MPH (Vanderbilt), and Dirk Schnappinger, PhD (WCM) have been awarded a five-year $30.8M, UM1 cooperative agreement award from NIAID/NIH to establish a consortium of tuberculosis preclinical and clinical experts to research the most effective treatment options for future clinical testing, called the Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium.
PReDicTR will establish a multidisciplinary consortium of scientific leaders, drug developers, and other stakeholders to comprehensively assess evolving preclinical research challenges and opportunities, with the goal of identifying novel regimens that have the greatest potential for clinical success in adults and children with TB.
Read more about the newly funded consortium in the UCSF press release found here
